NMN

Category: other

Aliases: nicotinamide mononucleotide

Pharmacological Mechanism

NAD+ precursor; supports sirtuin activity and cellular energy.

Half-Life (t½)

PO: 0.5h, SL: 0.5h

Dosing Guidelines

• PO: Typical 500 (Range: 250–1000)
• SL: Typical 250 (Range: 100–500)

Target Organ Systems

• endocrine
• musculoskeletal

Interactions

• Apigenin (synergistic): CD38 inhibition preserves NAD⁺ pool; pairs well with NMN precursor supply.
• TMG (synergistic): Methyl-donor support for NMN → NAD⁺ → methylated nicotinamide.
• NR (Nicotinamide Riboside) (synergistic): Parallel NAD⁺ precursor — NMN and NR ultimately converge at NAD⁺. Pick one.
• NAD⁺ (synergistic): Direct precursor via NMNAT.
• Resveratrol (synergistic): SIRT1 activation + NAD⁺ substrate supply. Classic longevity pair.
• Niacin (synergistic): All three (niacin, nicotinamide, NR/NMN) feed into NAD⁺; niacin is the cheapest and only one that raises HDL / lowers Lp(a), but causes flush.

Pathways It Modulates

• Cellular senescence / SASP / senolytics (cofactor) — NAD⁺ precursor → SIRT1/2 → SASP modulation
• Mitophagy (cofactor) — NAD⁺ precursor → SIRT-driven mitochondrial biogenesis + QC
• NAD+ / sirtuin / longevity axis (substrate) — NAD+ salvage (bypasses NAMPT)
• Niacin / NAD+ biosynthesis (substrate) — NMNAT pathway entry (nicotinamide mononucleotide; longevity supplement)
• Telomere maintenance + shelterin complex (cofactor) — NAD⁺ → SIRT1 → telomere stability

Chemical Identifiers

• PubChem CID: 14180
• Formula: C11H15N2O8P
• Molecular weight: 334.22 g/mol
• InChIKey: DAYLJWODMCOQEW-TURQNECASA-N
• SMILES: C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)[O-])O)O)C(=O)N

References

• PMID 34784420